Pair Name | Piceatannol, Everolimus | ||
Phytochemical Name | Piceatannol (PubChem CID: 667639 ) | ||
Anticancer drug Name | Everolimus (PubChem CID: 6442177 ) | ||
Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
Pair Name | Piceatannol, Everolimus | |||
Disease Info | [ICD-11: 2B72] | Gastric cancer | Investigative | |
Biological Phenomena | Induction-->Autophagy | |||
Gene Regulation | Up-regulation | Expression | BAX | hsa581 |
Down-regulation | Expression | BCL2 | hsa596 | |
Down-regulation | Phosphorylation | BECN1 | hsa8678 | |
Down-regulation | Expression | SQSTM1 | hsa8878 | |
In Vitro Model | SGC-7901 | Human papillomavirus-related cervical adenocarcinoma | Homo sapiens (Human) | CVCL_0520 |
In Vivo Model | 2×10⁶ SGC7901 cells were resuspended in phosphate-buffered saline (PBS) containing 50% Matrigel and engrafted subcutaneously into each flank of the mice. | |||
Result | The findings of this study strongly support the application of combinatorial piceatannol and everolimus therapy in future clinical trials for gastric cancer patients. |
No. | Title | Href |
---|---|---|
1 | Piceatannol enhances Beclin-1 activity to suppress tumor progression and its combination therapy strategy with everolimus in gastric cancer. Sci China Life Sci. 2023 Feb;66(2):298-312. doi: 10.1007/s11427-022-2185-9. | Click |